Travere Therapeutics (TVTX) EPS (Weighted Average and Diluted) (2016 - 2025)
Historic EPS (Weighted Average and Diluted) for Travere Therapeutics (TVTX) over the last 13 years, with Q3 2025 value amounting to $0.28.
- Travere Therapeutics' EPS (Weighted Average and Diluted) rose 14000.0% to $0.28 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.04, marking a year-over-year increase of 7714.29%. This contributed to the annual value of -$0.01 for FY2024, which is 9977.12% up from last year.
- Latest data reveals that Travere Therapeutics reported EPS (Weighted Average and Diluted) of $0.28 as of Q3 2025, which was up 14000.0% from -$0.14 recorded in Q2 2025.
- In the past 5 years, Travere Therapeutics' EPS (Weighted Average and Diluted) ranged from a high of $1.97 in Q3 2023 and a low of -$1.76 during Q1 2024
- Its 5-year average for EPS (Weighted Average and Diluted) is -$0.62, with a median of -$0.7 in 2024.
- Per our database at Business Quant, Travere Therapeutics' EPS (Weighted Average and Diluted) crashed by 490000.0% in 2021 and then soared by 25038.17% in 2023.
- Over the past 5 years, Travere Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$1.48 in 2021, then soared by 120.94% to $0.31 in 2022, then tumbled by 106.83% to -$0.02 in 2023, then surged by 100.24% to $0.0 in 2024, then soared by 552122.03% to $0.28 in 2025.
- Its EPS (Weighted Average and Diluted) was $0.28 in Q3 2025, compared to -$0.14 in Q2 2025 and -$0.47 in Q1 2025.